Pleural mesothelioma (PM) is an aggressive cancer typically linked to previous asbestos exposure.

Diagnosis relies on a high index of suspicion and often requires direct thoracoscopic biopsies with pleural fluid management.

Histopathological confirmation is crucial for prognostication.

Serum and pleural biomarkers might have a role to play in the future.